Healthtech Startups
17,200 companies tagged Healthtech, with their investors and founders.
Otomagnetics develops a non-invasive magnetic injection system to deliver drugs and therapeutic payloads to the inner and middle ear, the eye, and the skin, aimed at treating conditions such as inner ear diseases. The technology has demonstrated drug delivery to the inner and middle ear in animal models without puncturing the eardrum.
0 investors
0 investors
OTTO Health provides a video communication platform for healthcare providers to conduct virtual visits with patients across any device, integrating into existing clinical workflows.
0 investors
OTU Medical is a medical device company specializing in single-use urological endoscopes and minimally invasive visualization systems for urology procedures. The company operates with vertically integrated manufacturing capabilities across Silicon Valley and China, controlling the production of optoelectronic components, precision parts, and complete endoscope systems.
0 investors
0 investors
0 investors
0 investors
Outcome Referrals provides a behavioral health assessment and matching system called the Treatment Outcome Package (TOP) to connect patients with personalized mental health care and help payers implement value-based reimbursement models. The company serves healthcare providers, payers, and patients in the behavioral health sector.
0 investors
0 investors
HHI Surgery operates a surgical facility that provides outpatient clinical care for patients and serves as an extension of physician specialists' practices. It positions itself as a locally owned, state-of-the-art surgical center in the healthcare sector.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company that develops and markets branded generic and generic lamotrigine Starter Kits (Subvenite) for epilepsy and bipolar disorder in the U.S. Operating as a social enterprise, it donates profits to the ROW Foundation to support treatment of neurological disorders in under-resourced regions.
0 investors
Oxalo Therapeutics is a preclinical-stage biopharmaceutical company developing therapies to treat and prevent diseases caused by hyperoxaluria and hyperoxalemia, such as recurrent calcium oxalate kidney stones. Its microbiome-based approach mimics a natural mechanism using gut microbes to remove oxalate from the body.
0 investors
0 investors
Oxeia Biopharma develops therapeutics for concussion and brain injury treatment, focusing on moving beyond conservative management toward active clinical interventions.
0 investors
OxyDial develops technology to improve treatment and understanding of blood diseases, particularly sickle cell disease, for researchers and healthcare providers globally.
0 investors
OyaGen is a preclinical drug discovery and development company that identifies and optimizes lead compounds as investigational new drugs for infectious diseases and cancer, then licenses or partners them with industry leaders for clinical development. It also offers fee-for-service assay development and high throughput screening to academic and industry partners.
0 investors
PA Options for Wellness is a Pennsylvania medical cannabis company that cultivates and manufactures medical marijuana products, distributing them to qualified patients under the Vytal Options brand. It operates on a research-driven "Medical Model," partnering with universities on cannabis and hemp research to develop treatments tailored to specific medical conditions.
0 investors
Pace Surgical develops anatomically specific foot and ankle trauma and reconstruction devices designed by surgeons, including its Ultra Compression Screw System and Tempo Variable Locking Plating technologies. The products target foot and ankle surgeons in podiatry and orthopedic trauma care and are not yet FDA cleared.
0 investors
Pacific DT develops a patented prototype system emerging from university research with support from major health foundations and government agencies. The company is transitioning from research stage toward commercial clinical applications.
0 investors